Nectar Lifesciences Ltd.

NecLife

Ref: NLL\CS\2010-699 Dated: 28.09.2010

BY FAX / COURIER

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.

2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub. Investors Information Release

Dear Sirs,

Please find attached herewith an Investor Information release that the company has received approval from European Union (EU) for its' key product i.e. Cefuroxime Axetil.

This is for your information and record please.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited

Sunder Lal
Company Secretary

CC: 1. Singapore Exchange Securities Trading Limited,
2 Shenton Way, #19-00 SGX Centre 1, Singapore 068804,
Tel.: (0065) 6236 8888, Fax: (0065) 65357919.
Ref.: Common Code for Bonds: 024957900, ISIN for the Bonds: XS0249579003

2. Société de la Bourse de Luxembourg S.A., B.P. 165, L-2011 Luxembourg.
Telephone: (00352) 47 79 36 – 1, Fax: (00352) 47 32 98.
Ref.: Common Code for the GDRs: 039031680, ISIN for the GDRs: US63975T1051, CUSIP of Company's GDRs: 63975T 105

Corporate Office : S.C.O. 38-39, Sector 9-D, Chandigarh-160 009 (India) Tel. : +91-172-3047777 Fax : +91-172-3047755
E-mail : sales@neclife.com Website : www.neclife.com
Regd. Office & Works : Vill. Saidpura, Teh. Dera Bassi, Distt. Mohali (Punjab) Near Chandigarh (INDIA)
Tel. : +91-1762-308000, 308001 Fax : +91-1762-281187, 308135

DNV UKAS
ISO 9001:2008 Certified

NecLife
Nectar Lifesciences Ltd.

NECTAR LIFESCIENCES LIMITED
Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife granted 'Certificate of Suitability' for Cefuroxime Axetil in European Union

Chandigarh, September 28, 2010

Nectar Lifesciences Limited (NecLife), a leading USD 200 Mio integrated pharmaceutical organization with business interest across segments like API, P2P domestics & exports in ROW, Phytochemicals specially in Menthol & Empty hard gelatin capsule, today announced that it has been granted 'Certificate of Suitability' (No RO-CEP 2009-045-Rev 00) for its key molecule Cefuroxime Axetil in European Union (EU).

Business Opportunities in EU

Cefuroxime Axetil marketed by Innovator GSK as ZINNAT ™ in EU & CEFTIN ™ in US as tablets and Powder for Oral Suspension is a USD 710 million molecule globally, out of which, European sales constitute approximately 60% (USD 415 million). This translates into a huge opportunity for the Company as NecLife is indisputably largest global player in Cefuroxime Axetil in term of production capacity for APIs.

This is the 2nd approval for Nectar for Cefuroxime Axetil after Korean FDA approval for this molecule earlier in the month.

NecLife in the last one year has signed long term a contract with leading formulation marketing companies in South East Asia & Africa. NecLife is developing Cefuroxime Axetil tab (250mg & 500mg) & will file ANDA for US & MAA in EU within this financial year.

Commenting on this development, Mr. Dinesh Dua, CEO & Director of Nectar Lifesciences Limited said:

"We are encouraged with the progress of the initial steps undertaken to enter the regulated markets. The first half of the year has been a landmark year in terms of approvals and grants. The 'Certificate of Suitability' grant for Cefuroxime Axetil in the EU is a testimony to the

Nectar Lifesciences Ltd

efforts made by the Company to increase our reach and further entrench presence in the regulated markets. This is following the recent approval for Cefuroxime Axetil Amorphous in the Korea markets

We believe we are well poised to take advantage of the opportunities the new markets have to offer. We are also confident of our ability to further augment our position in the cephalosporin market in three major molecules and are making stable progress towards securing approvals in other key markets whilst delivering healthy growth."

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and semi-synthetic penicillin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 2 oral molecules and global No. 2 position in one sterile molecule. The Company has 11 manufacturing facilities - eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, semisynthetic, penicillin and other non-cephalosporin APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua
Nectar Lifesciences Limited
Phone: +91 172 304 7766
Fax: +91 172 503 3537
Email: dinesh.dua@neclife.com

Ishan Selarka
Citigate Dewe Rogerson
Phone : +91 22 4007 5032
Fax: 022 2284 4561
Email: ishan@cdr-india.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.